Novartis vows to fight US price-fixing claims

ZURICH, May 13 (Reuters): Novartis said on Monday claims of price fixing against its Sandoz generics unit amid a US probe of 20 drugmakers are without merit, with the Swiss company vowing to fight allegations in a lawsuit filed last week.

"We believe that these claims are without merit and will vigorously contest them," Novartis said. "Sandoz takes its obligations under the antitrust laws seriously.